Changes in Hong Kong stocks | Xuanzhu Bio-B (02575) rose more than 7% in early trading, the company issued a clarification announcement revealing that it is currently negotiating potential acquisitions

The Zhitong Finance App learned that Xuanzhu Bio-B (02575) rose more than 7% in early trading. As of press release, it rose 3.91% to HK$9.445, with a turnover of HK$26.7621 million.

According to the news, yesterday's intraday market news said that Xuanzhu Biotech signed a tripartite commercial agreement with Thailand's Innobic for pyroxil tablets. At one point, the stock soared more than 40%. Xuanzhu Biotech issued a clarifying announcement stating that it had noticed a rise in stock prices yesterday. After making an enquiry, the Board confirmed that it was unaware of any reason for the change, or any information required to be disclosed to avoid false stock markets, or any insider information required to be disclosed.

According to the announcement, preliminary discussions are currently under way with a party on a potential acquisition, and negotiations are still ongoing. The terms and conditions relating to the potential acquisition have not been implemented, and the Group has not entered into a formal agreement on the potential acquisition. There is no guarantee that a potential acquisition will be implemented or finalized. As a result, a potential acquisition may not necessarily take place.